Medical Advances and Optimal Treatment Approaches for Inflammatory Bowel Disease
The Centers for Disease Control (CDC) estimate that 1 to 1.3 million people suffer from inflammatory bowel disease (IBD) in the United States. These patients often require long-term management involving steroids, maintenance therapy with immunomodulators and biologicals, and acute interventions. During this activity, factors affecting the risk and course of IBD and the most updated protocols and guidelines for diagnosing and treating IBD will be discussed. New therapies targeting the immune process that are revolutionizing the treatment of IBD will also be presented.
At the end of this educational activity, participants should be able to:
- Discuss the medical advancements and optimal treatment approaches for IBD, including new therapies targeting the immune process.
- State the latest pharmaceutical and nonpharmaceutical treatments for IBD.
- Explain the role of the interprofessional team in optimizing patient-centered communication surrounding IBD.
- Recognize the environmental factors affecting the risk and course of IBD, including environmental triggers and the role of diet.
- Describe the latest vaccination recommendations for preventing infection in immunosuppressed patients with IBD.
Dermot McGovern, MD, PhD, FRCP (Lon)
Sarah Chart, RN
Rebecca Gleason, RN, CCM
Tina Rydland, PharmD
V. Silverstein, MD
Disclosures of Relevant Financial Relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education requires all those in the control of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content.
OptumHealth Education ensures that the content is independent of commercial bias.
Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.
Dr. McGovern has reported that he is a consultant for Cidara, QoBiologics, Janssen, Pfizer and Celgene.
The remaining activity faculty or planners have no financial relationships to disclose.
Method of participation
There are no fees for participating in or receiving credit for this activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Participants will receive a certificate upon successful completion of the activity, which includes the following:
- Completing the entire activity
- Completing the pre- and post-activity assessments, activity evaluation and application for certificate of credit
You must be logged into your account to participate in this activity. Get started by clicking "Begin" and viewing the "CE Info"; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under "My Account," "My Activities."
Method for Calculating CE Credit
CE credit was calculated by the complexity of content.
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credits for learning and change.
The participant will be awarded up to 0.75 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 0.75 contact hour(s) ([0.075] CEU) in states that recognize ACPE.
Attending the full program will earn 0.75 contact hour(s).
Unique Activity Number(s): JA0007123-0000-18-104-H01-P/T
OptumHealth Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 0.75 clock hour(s) for Certified Case Managers (CCM). (Please reference the 11th Annual Medical Director/Physician Leadership Forum when contacting CCMC to claim credit for this activity.)
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been pre-approved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization to which you wish you apply credit.
This activity is provided by OptumHealth Education.
No commercial support was received for this activity.
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software prior to the beginning of this activity.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals who are interested in inflammatory bowel disease.
This activity consists of recorded presentations from the "11th Annual Medical Director/Physician Leadership Forum" held in Las Vegas, NV on November 9, 2017.
- 0.75 ACPE - Pharmacist
- 0.75 ACPE - Pharmacy Technician
- 0.75 AMA
- 0.75 ANCC
- 0.75 Attendance
- 0.75 CCMC - General